

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 191 026 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
27.03.2002 Bulletin 2002/13

(51) Int Cl.7: **C07D 403/04**, C07D 237/08,
A61K 31/505, A61P 9/08

(21) Application number: **01307528.8**

(22) Date of filing: **05.09.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **20.09.2000 GB 0023074**


(71) Applicants:
• **Pfizer Limited**
Sandwich, Kent CT13 9NJ (GB)
Designated Contracting States:
GB
• **PFIZER INC.**
New York, N.Y. 10017 (US)
Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(72) Inventors:
• **Banks, Bernard Joseph**
Sandwich, Kent CT13 9NJ (GB)
• **Chubb, Nathan Anthony Logan**
Sandwich, Kent CT13 9NJ (GB)
• **Critcher, Douglas James**
Sandwich, Kent CT13 9NJ (GB)
• **Eshelby, James John**
Sandwich, Kent CT13 9NJ (GB)
• **Schulz, Darren John**
Groton, Connecticut 06340 (GB)

(74) Representative: **Motion, Keith Robert et al**
Pfizer Limited
Patents Department
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **New pyridazine endothelin antagonists**

(57) Compounds of formula (I) have affinity for endothelin receptors, are selective for ET_A over ET_B, and are potentially useful in the treatment of conditions mediated by endothelin.



EP 1 191 026 A1

Description

[0001] This invention relates to pyridazine derivatives useful in the treatment of a variety of conditions mediated by endothelin and to pharmaceutical formulations containing such compounds useful for the treatment of humans and non-human mammals.

[0002] Endothelin (ET) is a potent vasoconstrictor synthesised and released by endothelial cells. There are three distinct isoforms of ET: ET-1, ET-2 and ET-3, all being 21-amino acid peptides and herein the term 'endothelin' refers to any or all of the isoforms. Two receptor subtypes, ET_A and ET_B have been pharmacologically defined (see for example H. Arai et al., *Nature*, **348**, 730, 1990) and further subtypes have recently been reported. Stimulation of ET_A promotes vasoconstriction and stimulation of ET_B receptors causes either vasodilation or vasoconstriction. The main effects of ET are observed in the cardiovascular system, particularly in the coronary, renal, cerebral and mesenteric circulation, and the effects of endothelin are often long-lasting. Stimulation of ET receptors also mediate further biological responses in cardiovascular and non-cardiovascular tissues such as cell proliferation and matrix formation.

[0003] Increased circulating levels of endothelin have been observed in patients who have undergone percutaneous transluminal coronary angioplasty (PTCA) (A. Tahara et al., *Metab. Clin. Exp.*, 1991, **40**, 1235) and ET-1 has been found to induce neointimal formation in rats after balloon angioplasty (S. Douglas et al., *J. Cardiovasc. Pharm.*, 1993, **22** (Suppl 8), 371). The same workers have found that an endothelin antagonist, SB-209670, causes a 50% reduction in neointimal formation relative to control animals (S. Douglas et al., *Circ. Res.*, 1994, 75). Antagonists of the endothelin receptor may thus be useful in preventing restenosis post PTCA. The ET_{A/B} receptor antagonist Bosentan reportedly decreased blood pressure in hypertensive patients (H. Krum et al., *New Eng. J. Med.*, 1998, **338**, 784-790). Antagonists of ET_B receptors such as BQ-788 have been demonstrated to increase peripheral resistance in man (*Hypertension*, 1999, **33**, 581-585). Thus ET_A-selective receptor antagonists are of benefit in hypertension.

[0004] Endothelin-1 is produced in the human prostate gland and endothelin receptors have been identified in this tissue (Y. Saita et al., *Eur. J. Pharmacol.*, 1988, **349**, 123-128). Since endothelin is a contractile and proliferative agent, endothelin antagonists are useful in the treatment of benign prostate hypertrophy.

[0005] There is widespread localisation of endothelin and its receptors in the central nervous system and cerebrovascular system (R. K. Nikolov et al., *Drugs of Today*, 1992, **28**(5), 303) with ET being implicated in cerebral vasospasm, cerebral infarcts, septic shock, myocardial infarction and neuronal death.

[0006] Elevated levels of endothelin have also been observed in patients with:

- recurrent airway obstruction (*Pulm. Pharm. Ther.*, 1998, **11**: 231-235);
- asthma (*Am. J. Resp. Crit. Care Med.*, 1995, **151**:1034-1039);
- acute renal failure (K. Tomita, et al., *Med. Philos.*, 1994, **13**(1), 64-66);
- chronic renal failure (F. Stockenhuber et al., *Clin. Sci. (Lond.)*, 1992, **82**, 255);
- ischaemic Heart Disease (M. Yasuda, *Am. Heart J.*, 1990, **119**, 801);
- stable or unstable angina (J. T. Stewart, *Br. Heart J.*, 1991, **66**, 7);
- pulmonary hypertension (D. J. Stewart et al., *Ann. Internal Medicine*, 1991, **114**, 464);
- congestive heart failure (R. J. Rodeheffer et al., *Am. J. Hypertension*, 1991, **4**, 9A);
- preeclampsia (B. A. Clark et al., *Am. J. Obstet. Gynecol.*, 1992, **166**, 962);
- diabetes (A. Collier et al., *Diabetes Care*, 1992, **15**(8), 1038);
- Crohn's disease (S. H. Murch et al., *Lancet*, 1992, **339**, 381); and
- atherosclerosis (A. Lerman et al., *New Eng. J. Med.*, 1991, **325**, 997).

[0007] In every case the disease state associated with the physiologically elevated levels of endothelin is potentially treatable with a substance which decreases the effect of endothelin, such as an endothelin receptor antagonist, or a compound which binds endothelin such that it reduces the effective concentration thereof at the endothelin receptors.


[0008] Compounds that antagonise the ET_A receptor to a greater extent than the ET_B receptor are preferred as ET_A receptors are predominantly present in vascular smooth muscles. Blockade of ET_B receptor activation may reverse endothelial dependent vasodilation which is beneficial in hypertension. ET may also mediate regeneration of damaged tissue via the ET_B receptor, such as proximal tubule cells in the kidney. Thus blockade of ET_B receptors, e.g. with a non-selective ET antagonist could inhibit tissue repair. ET_B receptors are also involved in the clearance of ET from the systemic circulation. Increased levels of ET are generally considered detrimental. Rises in circulating levels have been observed with non-selective ET antagonists. Treatment with selective ET_A receptor antagonists are not likely to induce such rises in circulating levels.

[0009] There are a number of publications relating to N-(pyrimidin-4-yl)sulfonamide derivatives having endothelin binding / antagonist activity, for example EP-A-0743307, EP-A-0658548, EP-A-0633259, EP-A-0882719, WO-A-96/20177, EP-A-0801062, WO-A-97/09318, EP-A-0852226, EP-A-0768304, WO-A-96/19459, WO-A-98/03488, EP-A-0601386, EP-A-0510526 and EP-A-0713875.

[0010] Various *N*-4-pyrimidinyl sulfonamide derivatives possessing endothelin antagonist activity are described in JP-A-09059160, JP-A-10194972 and JP-A-10226649.

[0011] International Patent Application publication number WO-A-96/19455 discloses phenyl and pyridin-4-yl sulfonamides as endothelin antagonists.

[0012] We have unexpectedly found that pyridazines of formula (I) below have good affinity for endothelin receptors, and are selective for ET_A over ET_B. According to the present invention there are provided compounds of formula (I)



wherein:

R¹ is selected from (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl), (CR⁷R⁸)_n-het¹, (CR⁷R⁸)_n-aryl¹, NR⁹R¹⁰ and (CR⁷R⁸)_n-het², where R⁷ and R⁸ are independently selected from H and C₁₋₆ alkyl, and where R⁹ and R¹⁰ are independently selected from H or C₁₋₆ alkyl (optionally substituted by one of aryl¹, het¹, het² or (C₃₋₈ cycloalkyl));
n is 2-6;
R² is

- a) Phenyl, optionally fused with het¹ or het²,
- b) naphthyl, optionally fused with het¹ or het², or
- c) het²,

said groups (a), (b) and (c) optionally substituted by C₁₋₆ alkyl, O(C₁₋₆ alkyl), halo, het³, het⁴, aryl², CO₂R¹¹, OC(O)R¹¹, CONR¹¹R¹², S(O)_pR¹¹;
R³ is

- e) C₁₋₆ alkyl,
- f) C₂₋₆ alkenyl,
- g) C₂₋₆ alkynyl,
- h) C₃₋₈ cycloalkyl

Where groups (e), (f), (g) and (h) may be optionally substituted by OR¹¹, halo, NHC(O)C₁₋₆ alkyl, Ohet¹, Ohet², OC(O)NHhet¹, OC(O)NHhet², NH₂, NHC(O)Ohet², NHC(O)NHhet²;

X is O, S(O)_p, NH or a direct link;

Y is O, S(O)_p or NH;

p is 0, 1 or 2;

R⁴, R⁵ and R⁶ are each independently selected from

H, halo, S(O)_pR⁹, het¹, het², Aryl¹, O(C₁₋₆ alkyl) and C₁₋₆ alkyl (optionally substituted by halo, OR⁹ or NH₂);

R¹¹ and R¹² are independently selected from H and C₁₋₆ alkyl;

wherein "aryl¹" is a C₆₋₁₄ aromatic carbocycle, including mono-, bi- and tri-cyclic systems;

"aryl²" is a C₆₋₁₀ aromatic carbocycle, including mono- and bi-cyclic systems;

"het¹" is a 3-8 membered ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being saturated or partially unsaturated and optionally benzofused;

5 "het²" is a 5 or 6 membered aromatic ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being optionally benzofused;

"het³" is a 3-6 membered ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being saturated or partially unsaturated and optionally benzofused;

10 "het⁴" is a 5 or 6 membered aromatic ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being optionally benzofused;

and wherein "het¹", "het²" and "aryl¹" may optionally be substituted by 1 to 3 substituents independently selected from

15 halo, CO₂R⁹, OCOR⁹, OH, het⁴, S(O)_pR¹¹, O(C₁₋₆alkyl), or C₁₋₆ alkyl (optionally substituted by OH, O(C₁₋₆ alkyl) or halo);

halo includes fluoro, chloro, bromo and iodo groups;

20 a 6-14 membered aromatic carbocycle includes phenyl, naphthyl, indenyl, anthryl and phenanthryl;

alkyl includes straight chain and branched chain alkyl groups;

and the pharmaceutically acceptable salts, solvates and polymorphs thereof.

25 **[0013]** A pharmaceutically acceptable salt of a compound of the formula (I) may be readily prepared by mixing together solutions of a compound of the formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

[0014] The pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition and the base salts thereof.

30 **[0015]** Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, *p*-toluenesulphonate and pamoate salts.

35 **[0016]** Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.

[0017] For a review on suitable salts see Berge *et al.*, *J. Pharm. Sci.*, **66**, 1-19, 1977.

[0018] The pharmaceutically acceptable solvates of the compounds of the formula (I) include the hydrates thereof.

[0019] Also included within the present scope of the compounds of the formula (I) are polymorphs thereof and polymorphs of pharmaceutically acceptable salts and solvates.

40 **[0020]** It will also be appreciated that the compounds of the invention will include prodrugs thereof: pharmaceutically acceptable derivatives of (I) in which the functional groups explicitly recited above have been derivatised to provide prodrugs which can be converted to the parent compound *in vivo*. Such prodrugs are discussed in *Drugs of Today*, Vol. 19, 499-538 (1983) and *Annual Reports in Medicinal Chemistry*, Vol. 10, Ch 31 p306-326.

45 **[0021]** A compound of the formula (I) may contain one or more asymmetric carbon atoms and therefore exists in two or more stereoisomeric forms. Where a compound of the formula (I) contains an alkenyl or alkenylene group, *cis/trans* (or *E/Z*) isomerism may also occur. The present invention includes the individual stereoisomers of the compounds of the formula (I) and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.

[0022] Racemic substances may either be separated using preparative HPLC and a column with a chiral stationary phase or resolved to yield individual enantiomers utilising methods known to those skilled in the art. In addition, chiral intermediates may be resolved and used to prepare chiral compounds of formulae (I).

50 **[0023]** Preferred compounds of formula (I) are those where the pyrimidine ring is attached at the 3 or 4 position of the pyridazine ring.

[0024] Preferably R¹ is (CR⁷R⁸)_n-aryl¹, (CR⁷R⁸)_n-het² or (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl) and where n is 2, 3, 4, 5 or 6.

More preferably R¹ is (CR⁷R⁸)_n-aryl¹ or (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl) and where n is 2 or 3.

55 Most preferably R¹ is (CR⁷R⁸)_n-aryl¹ or (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl) and where n is 2.

[0025] Preferably R² is phenyl or het², both optionally substituted by C₁₋₆ alkyl, O(C₁₋₆ alkyl), halo, het³, het⁴, aryl², CO₂R¹¹, OC(O)R¹¹ or CONR¹¹R¹².

More preferably R² is phenyl optionally substituted by C₁₋₆ alkyl, O(C₁₋₆ alkyl), halo, het³, het⁴, aryl², CO₂R¹¹, OC(O)

R¹¹ or CONR¹¹R¹².

Most preferably R² is phenyl optionally substituted by C₁₋₃ alkyl, O(C₁₋₃ alkyl), F or Cl.

[0026] Preferably R³ is C₁₋₆ alkyl, C₂₋₆ alkynyl or C₃₋₈ cycloalkyl, said alkyl, alkynyl and cycloalkyl groups optionally substituted by

5 OR¹¹, halo, NHC(O)C₁₋₆ alkyl, Ohet¹, Ohet², OC(O)NHhet¹ or OC(O)NHhet². More preferably R³ is C₂₋₃ alkynyl or C₁₋₃ alkyl (optionally substituted by OR¹¹, halo, NHC(O)C₁₋₆ alkyl, Ohet¹, Ohet², OC(O)NHhet¹ or OC(O)NHhet²). Most preferably R³ is C₁₋₃ alkyl, CH₂CH₂OH, CH₂C≡CH, CH₂CH₂F or CH₂CH₂OCH₃.

[0027] Preferably R⁴, R⁵ and R⁶ are selected from H, O(C₁₋₆ alkyl), S(C₁₋₆alkyl), phenyl, halo, het¹, het² and C₁₋₆ alkyl (optionally substituted by halo or NH₂).

10 More preferably R⁴ and R⁵ are hydrogen and R⁶ is selected from H, O(C₁₋₆ alkyl) and C₁₋₆ alkyl (optionally substituted by halo).

[0028] Most preferably R⁴ and R⁵ are hydrogen and R⁶ is selected from H or C₁₋₆alkyl.

[0029] Preferably R⁷ and R⁸ are independently selected from H and C₁₋₃ alkyl.

More preferably R⁷ and R⁸ are independently selected from H and CH₃.

15 Most preferably R⁷ and R⁸ are H.

[0030] Preferably R⁹ and R¹⁰ are selected from H and C₁₋₃ alkyl (optionally substituted by aryl¹, het¹, het² and C₃₋₈cycloalkyl).

More preferably R⁹ and R¹⁰ are selected from H and C₁₋₃ alkyl (optionally substituted by aryl¹ or het¹).

Most preferably R⁹ and R¹⁰ are H.

20 **[0031]** Preferably R¹¹ and R¹² are selected from H and C₁₋₃ alkyl.

More preferably R¹¹ and R¹² are selected from H and CH₃.

[0032] Preferably X is O, NH or a direct link.

Most preferably X is O.

[0033] Preferably Y is O or NH.

25 Most preferably Y is O.

[0034] Preferably n is 2, 3 or 4.

Most preferably n is 2.

[0035] A preferred set of compounds are those described in the Examples and pharmaceutical derivatives thereof.

30 **[0036]** The invention further provides methods for the production of the compounds of the invention, which are described below and in the Examples and Preparations section. The skilled man will appreciate that the substances of the invention could be made by methods other than those herein described, by adaptation of the methods herein described and/or adaptation of a plethora of methods known in the art. It is to be understood that the synthetic transformation methods specifically mentioned herein may be carried out in various different sequences in order that the desired substances can be efficiently assembled. The skilled chemist will exercise his judgement and skill as to the
35 most efficient sequence of reactions for synthesis of a given target substance.






[0037] It will be apparent to those skilled in the art that sensitive functional groups may need to be protected and deprotected during synthesis of a substance of the invention. This may be achieved by conventional techniques, for example as described in 'Protective Groups in Organic Synthesis' by T W Greene and P G M Wuts, John Wiley and Sons Inc, 1991.

40 **[0038]** Compounds of formula (I) may be prepared in accordance with the following reaction scheme. Unless otherwise specified, the substituents are as defined above with reference to the compounds of formula (I) above.

45

50

55



[0039] Compounds of formula (IV) may be prepared from compounds of formula (V) and (VI), where R^{10a} is a C_{1-6} alkyl or phenyl group, by process step (i), a condensation reaction. This is typically conducted in the presence of $R^{10a}ONa$ in a solvent of the corresponding alcohol $R^{10a}OH$.


[0040] Compounds of formula (III) may be prepared by treating compounds of formula (IV) with a chlorinating agent in process step (ii), using, for example, $SOCl_2$ or phosphorus oxychloride in the presence of a base which may be inorganic eg. sodium hydrogen carbonate or organic eg. diethylisopropylamine. The reaction is optionally conducted employing an inert solvent eg. tetrahydrofuran, optionally cooled or heated, and when tetrahydrofuran is used as solvent, preferably reacted at 60-65°C.

[0041] Compounds of formula (II) may be prepared under the conditions of process step (iii), treating compounds of formula (III) with $R^1SO_2NH_2$ in the presence of a base such as potassium carbonate. The reaction requires heat and should be conducted in a suitable solvent such as DMSO.

[0042] $R^1SO_2NH_2$ may be prepared by treating the corresponding bromide with Na_2SO_3 in water/DME, followed by PCl_5 in eg toluene or $POCl_3$, followed by reaction with eg aqueous NH_3 in ethanol. R^1Br is commercially available or may be prepared by methods well known to the man skilled in the art.

[0043] Compounds of formula (I) may be prepared under the conditions of process step (iv) reacting compounds of formula (II) with R^3YH in the presence of a suitable base (eg NaH) and solvent. R^3YH is used as a solvent where suitable, with optional use of an inert solvent eg. tetrahydrofuran or dimethylformamide, and optional heat.

[0044] Compounds of formula (V) may be prepared in accordance with the following reaction schemes.



[0045] Compounds of formula (V) may be prepared under the conditions of process step (v), treating a compound of formula (VII) with an alkoxide in a solvent of the corresponding alcohol, such as methoxide in methanol, followed by reaction with NH_4Cl . Synthesis of pyridazinecarbonitriles can be found in the literature, such as Dostal *et al.*, *Heterocycles* (1986), 24(3), 793-7.

[0046] The introduction and transformation of functional groups on aromatic heterocycles is well described in the literature and the principles can be applied to provide the desired pyridazines by one of ordinary skill in the art. Literature references include Tisler *et al.*, *Adv. Heterocycl. Chem* (1990), 49 385-474 and Heinisch, *Bull. Soc. Chim. Belg.* (1992), 101(7), 579-96.

[0047] Compounds of formula (VI) may be prepared in accordance with the following reaction scheme.



20

25

30



35

40

45

50

55




35


[0050] Compounds of formula (IA) are reacted under the conditions of process step (vii) with an agent to activate the alcohol such as phosgene or carbonyldiimidazole. This intermediate is then reacted under the conditions of process step (viii) with $\text{H}_2\text{N-het}^2$ in the presence of a suitable base such as triethylamine to give (IB).

40

Compounds of formula (IA) where R^1 , R^2 , R^4 , R^5 , R^6 and X are as described above and the YR^3 chain is $\text{OCH}_2\text{CH}_2\text{OH}$, with the proviso that R^4 , R^5 and R^6 are not CO_2R^9 or alkyl chloride or bromide, may be further elaborated to give the corresponding compound of formula (IC) where YR^3 is $\text{OCH}_2\text{CH}_2\text{Ohet}^2$. These compounds may be prepared in accordance with the following reaction scheme.



(ix)



[0051] Compounds of formula (IA) were treated under the conditions of process step (ix) which comprised reaction with het²-Z, where Z is a suitable leaving group such as halo or SO₂Me, in the presence of a suitable base such as sodium hydride.

[0052] Compounds of formula (ID) where R¹, R², R³, R⁴, R⁵, Y and X are as described above and R⁶ is CO₂R⁹, with the proviso that there are no other ester, ketone or hydroxy moieties within the molecule, may be further elaborated to give the corresponding compound of formula (IF) where R⁶ is CH₂F or (IG) where R⁶ is CF₂H. These compounds may be prepared in accordance with the following reaction scheme.

5

10

15

20

25

30


35

40

45

50

55



[0053] Compounds of formula (ID) are treated under the conditions of process step (x) a reduction, with a suitable reagent such as DIBAL or LiAlH_4 to give the corresponding alcohol (IE). The alcohol may be oxidised to an aldehyde via process step (xi) using a suitable oxidant such as pyridinium dichromate or MnO_2 , followed by fluorination in process

step (xii) by reaction with a suitable fluorinating agent such as diethylaminosulfur trifluoride (DAST) to give compound (IG). Compounds of formula (IE) may also be converted to compounds of formula (IF) under the conditions of process step (xii) described above.

[0054] The compounds of the invention may be separated and purified by conventional methods.

5 **[0055]** The substances of the invention are useful because they blockade ET receptors and are thus useful in the treatment or prevention of any diseases for which such a blockade is beneficial. More particularly, they are useful in the treatment and prevention of restenosis, acute/chronic renal failure, hypertension including pulmonary and systemic hypertension; benign prostatic hypertrophy, male erectile dysfunction, prostate cancer, metastatic bone cancer, congestive heart failure, stroke, subarachnoid haemorrhage, angina, atherosclerosis, cerebral and cardiac ischaemia, prevention of ischaemia/reperfusion injury (e.g. allografts), cyclosporin induced nephrotoxicity, glaucoma, radiocontrast nephropathy, diabetic neuropathy, allergy, restoration of organ perfusion in haemorrhagic shock, lipoprotein lipase related disorders, chronic obstructive pulmonary disease and hyaline membrane disease in newborn. The treatment of congestive heart failure, restenosis, renal failure and systemic and pulmonary hypertension are of particular interest. The substances of the invention may be administered alone or as part of a combination therapy.

15 **[0056]** The invention also provides a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use as medicament.

[0057] The invention also provides for the use of a compound of formula (I) or pharmaceutically acceptable derivative thereof as defined above, in the manufacture of a medicament for the treatment of conditions mediated by endothelin, particularly ET_A, more particularly restenosis, acute/chronic renal failure, pulmonary hypertension, systemic hypertension; benign prostatic hyperplasia, male erectile dysfunction, prostate cancer, metastatic bone cancer, congestive heart failure, stroke, subarachnoid haemorrhage, angina, atherosclerosis, cerebral and cardiac ischaemia, prevention of ischaemia/reperfusion injury (e.g. allografts), cyclosporin induced nephrotoxicity, glaucoma, radiocontrast nephropathy, diabetic neuropathy, allergy, restoration of organ perfusion in haemorrhagic shock, lipoprotein lipase related disorders, chronic obstructive pulmonary disease and hyaline membrane disease in newborn.

25 **[0058]** The invention also provides a method of treating conditions mediated by endothelin, particularly ET_A, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

[0059] Reference to treatment herein includes prevention of undesirable conditions as well as alleviation or cure of said conditions.

30 **[0060]** The biological activity of the substances of the invention may be demonstrated as follows:

Human Binding assay

35 **[0061]** Competition between test substances and ¹²⁵I-ET-1 binding to human endothelin receptors is determined as follows.

Binding to ET_A receptors

40 **[0062]** 25μl of a 30pM solution of [¹²⁵I]Tyr¹³ ET-1 (specific activity 2,200Ci/mM) is mixed with 25μl samples of test substance (final concentrations in the range 0.1nM - 50,000nM). 200μl of a solution containing cloned human ET_A receptor (0.75pmoles receptor protein/ml), 50mM Tris, 0.5mM CaCl₂, 0.1% human serum albumen, 0.1% bacitracin, 0.05% Tween 20, pH 7.4 is added. The solution is mixed at 37°C for 2 hours. After the incubation, the unbound ligand is separated from receptor bound ligand by filtration with a Brandel cell harvester, followed by three washes of buffer. Filter papers are counted for radioactivity, and the IC₅₀ (the concentration of test compound at which 50% of the radio-labelled compound is unbound) determined for the concentration range tested.

Binding to ET_B receptors

50 **[0063]** 25μl of a 30pM solution of [¹²⁵I]Tyr¹³ ET-1 (specific activity 2,200Ci/mM) is mixed with 25μl samples of test substance (final concentration 0.1nM - 50,000nM). 200μl of a solution containing cloned human ET_B receptor (0.25pmoles receptor protein/ml), 50mM Tris, 0.5mM CaCl₂, 0.1% human serum albumen, 0.1% bacitracin, 0.05% Tween 20, pH 7.4 is added. The solution is mixed at 37°C for 2 hours. After the incubation, the unbound ligand is separated from receptor bound ligand by filtration with a Brandel cell harvester, followed by three washes of buffer. Filter papers are counted for radio-activity, and the IC₅₀ (the concentration of test compound at which 50% of the radio-labelled compound is unbound) determined for the concentration range tested.

55 **[0064]** The compounds of the present invention were tested and found to have good affinity for endothelin receptors and to be selective for ET_A over ET_B.

Dog Binding assay

[0065] Competition between test substances and ligands binding to canine endothelin receptors is determined as follows:

Dog ET_A Binding Assay

[0066] 50µl of a 500pM solution of ¹²⁵I-PD-151242 (Specific activity 2,000 Ci/mM) is mixed with 50µl samples of test substances (final concentrations in the range from 0.01-10,000nM). 100µg of purified dog kidney homogenate is added in 150µl of the following buffer: 50mM Tris, 10mM MgCl₂ and 0.05% Bovine Serum Albumen at pH 7.4. The solution is incubated at room temperature for 2 hours. After the incubation, the unbound ligand is separated from receptor bound ligand by filtration with a Brandel cell harvester, followed by 5 washes with buffer (Tris 50mM, MgCl₂ 10mM). Filter papers are counted for radioactivity and the K_i (an IC₅₀ corrected for the dissociation constant and concentration of the ligand added) is determined for the concentration range tested.

Dog ET_B Binding Assay

[0067] 50µl of a 100pM solution of ¹²⁵I-IRL-1620 (Specific activity 2,200 Ci/mM) is mixed with 50µl samples of test substances (final concentrations in the range from 0.01-10,000nM). 50µg of purified Dog cerebellum homogenate is added in 150µl of the following buffer; 50mM Tris, 10mM MgCl₂ and 0.05% Bovine Serum Albumen at pH 7.4. The solution is incubated at 30°C for 90 minutes. After the incubation, the unbound ligand is separated from receptor bound ligand by filtration with a Brandel cell harvester, followed by 5 washes with buffer (Tris 50mM, MgCl₂ 10mM). Filter papers are counted for radioactivity and the K_i (an IC₅₀ corrected for the dissociation constant and concentration of the ligand added) is determined for the concentration range tested.

[0068] The compounds of the present invention were investigated using the above assay and demonstrated strong ET_A affinity and a marked selectivity for the ET_A over the ET_B receptor. Of the compounds disclosed, the compound of example 5 displays affinity and selectivity for the dog ET_A receptor (K_i 2nM) vs dog ET_B (K_i 132nM).

[0069] According to a further aspect of the invention, there are provided pharmaceutical formulations comprising a substance of the invention, as defined above, and a pharmaceutically-acceptable adjuvant, diluent or carrier.

[0070] The substances of the invention can be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. For example they can be administered orally in the form of tablets containing such excipients as starch or lactose or in capsules or ovules either alone or in admixture with excipients or in the form of elixirs, solutions or suspensions containing the substance in a liquid carrier, for example a vegetable oil, glycerine or water with a flavouring or colouring agent. They can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parental administration, they are best used as sterile aqueous solutions which may contain other substances, for example, enough glucose or salts to make the solution isotonic with blood. For parenteral administration the substance may also be administered as a solution or suspension in a suitable oil, for example polyethylene glycol, lecithin or sesame oil.

[0071] Substances of the invention may also be administered through inhalation of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane.

[0072] For oral or parenteral administration to human patients the daily dosage levels of substances of the invention will be from 0.01 to 30 mg/kg (in single or divided doses) and preferably will be in the range 0.01 to 5 mg/kg. Thus tablets will contain 1mg to 0.4g of substance for administration singly or two or more at a time, as appropriate. The above dosages are, of course only exemplary of the average case and there may be instances where higher or lower doses are merited, and such are within the scope of the invention.

General Example

[0073] A formulation of the tablet could typically contain between about 0.01 mg and 500mg of active compound whilst tablet fill weights may range from 50mg to 1000mg. An example of a formulation for a 10mg tablet is illustrated below:

Ingredient	%w/w
Free acid, Free base or Salt form of active compound	10.000
Lactose	64.125

(continued)

Ingredient	%w/w
Starch	21.375
Croscarmellose sodium	3.000
Magnesium Stearate	1.500

[0074] The tablets are manufactured by a standard process, for example, direct compression or a wet or dry granulation process. The tablet cores may be coated with appropriate overcoats.

[0075] Alternatively the substances of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder or in the form of a medicated plaster, patch or membrane. For example they may be incorporated in a cream containing an aqueous emulsion of polyethylene glycols or liquid paraffin. The compounds may also be administered intranasally.

[0076] For veterinary use although it is possible to administer a substance of the invention directly without any formulation, the substances are preferably employed in the form of a pharmaceutical or veterinary formulation comprising a pharmaceutically or veterinarily acceptable carrier, diluent or excipient and a substance of the invention. Such compositions will contain from 0.1 percent by weight to 90.0 percent by weight of the active ingredient.

[0077] The methods by which the compounds may be administered include oral administration by capsule, bolus, tablet or drench, topical administration as an ointment, a pour-on, spot-on, dip, spray, mousse, shampoo or powder formulation or, alternatively, they can be administered by injection (e.g. subcutaneously, intramuscularly or intravenously), or as an implant.

[0078] Such formulations are prepared in a conventional manner in accordance with standard veterinary practice. Thus capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier additionally containing a disintegrating agent and/or binder such as starch, lactose, talc or magnesium stearate, etc. Oral drenches are prepared by dissolving or suspending the active ingredient in a suitable medium. Pour-on or spot-on formulations may be prepared by dissolving the active ingredient in an acceptable liquid carrier vehicle such as butyl digol, liquid paraffin or a non-volatile ester, optionally with the addition of a volatile component such as propan-2-ol.

[0079] Alternatively, pour-on, spot-on or spray formulations can be prepared by encapsulation, to leave a residue of active agent on the surface of the animal. Injectable formulations may be prepared in the form of a sterile solution which may contain other substances, for example enough salts or glucose to make the solution isotonic with blood. Acceptable liquid carriers include vegetable oils such as sesame oil, glycerides such as triacetin, esters such as benzyl benzoate, isopropyl myristate and fatty acid derivatives of propylene glycol, as well as organic solvents such as pyrrolidin-2-one and glycerol formal. The formulations are prepared by dissolving or suspending the active ingredient in the liquid carrier such that the final formulation contains from 0.1 to 10% by weight of the active ingredient.

[0080] These formulations will vary with regard to the weight of active substance contained therein, depending on the species of animal to be treated, the severity and type of infection and the body weight of the animal. For parenteral, topical and oral administration, typical dose ranges of the active ingredient are 0.01 to 100 mg per kg of body weight of the animal. Preferably the range is 0.1 to 10 mg per kg.

[0081] The compositions are preferably formulated in a unit dosage form, each dosage containing from about 1 to about 500 mg, more usually about 5 to about 300 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.

[0082] As an alternative for veterinary use the substances may be administered with animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.

[0083] The compounds of the formula (I) may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

EXAMPLES AND PREPARATIONS


[0084] High performance liquid chromatography (HPLC) retention times and UV spectra were recorded using a

Hewlett-Packard 1090 LUSI diode-array spectrophotometer (method A). All NMR spectra were measured in CDCl_3 or MeOD by an Inova 300 MHz or 400 MHz spectrometer unless otherwise indicated and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br broad. High resolution MS data was acquired on an AutoSpecQ with electrospray ionisation (ESI) or thermospray ionisation (TSPI) using a PEG reference (or on a Bruker Apex II FTMS with ESI where indicated). All calculated MS values for compounds including Cl are based on the ^{35}Cl isomer. All IR spectra were recorded using a Perkin Elmer Paragon 1000 FT-IR.

PREPARATION 1

3-Pyridazinecarboximidamide hydrochloride

[0085]




[0086] Sodium methoxide (25% w/v in methanol, 0.3ml, 1.3 mmol) was added in one portion to a stirred solution of 3-cyanopyridazine (2.4g, 22.9 mmol) (Ref. *Heterocycles*, **1986**, 24(3), 793) in methanol (10ml). The resulting mixture was stirred at room temperature for 16 hours. Ammonium chloride (2.45g, 45.8 mmol) was added to the reaction mixture, which was then stirred for 30 minutes before being ultrasonicated for a further 15 minutes. A fine, yellow precipitate was observed after this time. The solvent was evaporated under vacuum and the residue was suspended in ethanol (150ml) and heated to reflux for 5 minutes. The hot mixture was filtered (gravity) to remove unreacted ammonium chloride and sodium chloride and was then cooled to room temperature. A pale yellow, crystalline solid formed upon cooling and this was isolated by suction filtration to give the title compound (2.03g), m.p. 234 - 241°C. $^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$): δ 8.08 (dd, 1H), 8.54 (d, 1H), 9.53 (d, 1H) ppm. IR (KBr disk): λ 1404, 1692, 3040, 3143, 3431, 3469 cm^{-1} .

Preparation 2

5-(2-Methoxyphenoxy)-2-(3-pyridazinyl)-4,6-pyrimidinediol

[0087]



[0088] Dimethyl 2-(2-methoxyphenoxy)malonate (3.05g, 12.6mmol) (Ref. Canadian Patent Application CA2071193A, 1992) in methanol (15ml) was added over 5 minutes to a stirred, 25% w/v solution of sodium methoxide in methanol (8.58ml, 37.8mmol of sodium methoxide) at room temperature. The resulting mixture was stirred for 10 minutes and then a solution of 3-pyridazinecarboximidamide hydrochloride (2.0g, 12.6mmol) in methanol (15ml) was added dropwise over 5 minutes and the resulting mixture was stirred at room temperature overnight. The reaction

mixture was concentrated under vacuum and then diluted with water (100ml). The aqueous solution was acidified to pH 4 with sulfuric acid (20%), resulting in the formation of the title compound as a purple solid, which was isolated by filtration (1.4g).


¹H-NMR (300 MHz, DMSO-d₆): δ 3.83 (s, 3H), 6.68 (d, 1H), 6.78 (t, 1H), 6.93 (t, 1H), 7.03 (d, 1H), 7.94 (dd, 1H), 8.34 (d, 1H), 9.43 (d, 1H) ppm.

HRMS (+ve ion) found: m/z 313.0929 (MH⁺). C₁₅H₁₂N₄O₄+H requires m/z 313.0932

PREPARATION 3

3-[4,6-Dichloro-5-(2-methoxyphenoxy)-2-pyrimidinyl]pyridazine

[0089]



[0090] A solution of 5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4,6-pyrimidinediol (1.4g, 4.5mmol) and diisopropylethylamine (1.28g, 9.9mmol) in phosphorus oxychloride (7ml) was stirred for 1 hour at room temperature under a nitrogen atmosphere and then heated under reflux for 1 hour before being cooled to room temperature and stirred for 72 hr. The reaction mixture was heated under reflux for a further 7 hours and then again cooled to room temperature and stirred for a further 16 hours.

The reaction mixture was added slowly to a stirred aqueous solution of hydrochloric acid (0.1M, 200ml) at 50°C over 20 minutes. A precipitate formed and was isolated by filtration. The isolated crude product was purified by chromatography on a Biotage® Flash 40(s) silica cartridge (40g) using 70% ethyl acetate/ heptane as eluant to give the title compound as a light brown solid (1.1g), R_f 0.59 (ethyl acetate).


¹H-NMR (300 MHz, CDCl₃): δ 3.86 (s, 3H), 6.79 (d, 1H), 6.91 (t, 1H), 7.02 (d, 1H), 7.13 (t, 1H), 7.72 (dd, 1H), 8.58 (dd, 1H), 9.36 (d, 1H) ppm.

HRMS (+ve ion) found: m/z 349.0247 (MH⁺). C₁₅H₁₀³⁵Cl₂N₄O₂+H requires m/z 349.0253.

PREPARATION 4

2-(4-Fluorophenyl)ethanesulfonic acid sodium salt

[0091]




[0092] A mixture of 2-(4-fluorophenyl)ethyl bromide (1.8g, 8.9mmol) (Ref. *Chim. Ther.*, 1969, 4(3), 185) and sodium sulfite (2.24g, 8.9mmol) in water (5ml) and dimethoxyethane (5ml) was heated under reflux for 21 hours. The mixture was then left for 72 hours at room temperature. The mixture was concentrated under vacuum to leave the title compound as a crystalline mixture with sodium bromide (2.87g).

¹H-NMR (300 MHz, D₂O): δ 2.96 (m, 2H), 3.09 (m, 2H), 7.03 (dd, 2H), 7.25 (dd, 2H) ppm.

LRMS (-ve ion) found: m/z 203 (M⁻). C₈H₈FO₂S requires 203.

[0093] The following examples were also prepared by a similar method to that described for preparation 4.




Preparation No.	R	Reference/ source (starting material)	Analytical data
5		<i>J. Med. Chem.</i> , 1997, 40(16), 2502	¹ H-NMR (300 MHz, D ₂ O): δ 3.08 (t, 2H), 3.15 (t, 2H), 3.86 (s, 3H), 7.37 (d, 2H), 7.91 (d, 2H) ppm. MS – no ionisation
6		<i>J. Med. Chem.</i> , 1981, 24(4), 404	¹ H-NMR (300MHz, D ₂ O): δ 0.8 – 1.65 (m, 10H), 1.75 (m, 1H), 2.80 (t, 2H) ppm.

PREPARATION 7

2-(4-Fluorophenyl)ethanesulfonyl chloride

[0094]



[0095] Phosphorus pentachloride (5.6g, 27mmol) was added portionwise over 10 minutes to a stirred suspension of 2-(4-fluorophenyl)ethanesulfonic acid sodium salt (9mmol, contaminated with sodium bromide, total weight 2.87g) in dry toluene (15ml) at room temperature. The reaction mixture was heated under reflux for 90 minutes and was then stirred at room temperature overnight. The reaction mixture was diluted with water (20ml) and the organic phase was separated. The aqueous phase was extracted with dichloromethane (20ml) and the organic extracts were combined, dried over magnesium sulfate and concentrated under vacuum to give the title compound as an oil, (0.7g) R_f 0.92


(dichloromethane).

¹H-NMR (300 MHz, CDCl₃): δ 3.33 (m, 2H), 3.89 (m, 2H), 7.07 (dd, 2H), 7.23 (dd, 2H) ppm.

IR (NaCl disk): λ 1599, 1509, 1450, 1354 cm⁻¹

[0096] The following compounds were prepared by similar methodology.




Preparation No.	R	Yield	Analytical data
8		1.5g	¹ H-NMR (300 MHz, CDCl ₃): δ 3.24 (t, 2H), 3.58 (t, 2H), 3.92 (s, 3H), 7.28 (d, 2H), 8.00 (d, 2H) ppm. MS m/z 260 (MNH ₄ ⁺) IR λ 2952, 1721, 1611, 1435, 1280, 1180cm ⁻¹

PREPARATION 9

2-(Cyclopentyl)ethylsulfonfyl chloride

[0097]



[0098] Dimethylformamide (5 drops) was added over 1 minute to a stirred solution of 2-(cyclopentyl)ethylsulfonic acid sodium salt (15.5g, 87.5mmol) in thionyl chloride (60ml) under a nitrogen atmosphere. The reaction mixture was stirred under reflux for 5 hours and was then cooled to room temperature and concentrated under vacuum. The residue was suspended in toluene (100ml) and then concentrated under vacuum. The residue was dissolved in a mixture of ethyl acetate (150ml) and water (150ml) and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (100ml) and the combined organic extracts were washed with brine (3 x 100ml), dried (magnesium sulfate) and evaporated to give the title compound as a brown oil (14.1g), R_f 0.5 (pentane/ethyl acetate 95:5).

¹H-NMR (300 MHz, CDCl₃): δ 1.15 (m, 2H), 1.50 -1.72 (m, 4H), 1.84 (m, 2H), 1.91 (m, 1H), 2.03 (m, 2H), 3.66 (m, 2H) ppm.


PREPARATION 10

2-(4-Fluorophenyl)ethanesulfonamide

5 [0099]

10

15



20

25

[0100] A mixture of 2-(4-fluorophenyl)ethanesulfonyl chloride (0.7g, 3.3mmol) and concentrated aqueous ammonia (0.88 specific gravity, 10ml) in ethanol (5ml) was stirred at room temperature overnight. The reaction mixture was diluted with water (10ml), acidified to pH 4 with citric acid (1.0M) and then extracted with dichloromethane. The organic extracts were dried by filtering through an organic-only, permeable membrane and then concentrated under vacuum. The residue was purified by chromatography on a Biotage® Flash 40 (s) column (40g silica) using 10 - 20% ethyl acetate/dichloromethane as eluant to give the title compound as an off white solid, (0.66g).

¹H-NMR (300 MHz, CDCl₃): δ 2.98 (m, 2H), 3.23 (m, 2H), 7.11 (dd, 2H), 7.29 (dd, 2H) ppm.

IR (KBr disk): λ 3357, 3254, 3068, 2962, 1907, 1598, 1509, 1321, 1161 cm⁻¹ LRMS (-ve ion) found: m/z 202 (M-H).

C₈H₁₀FNO₂S - H requires m/z 202

[0101] The following compounds were prepared by similar methodology.

30


35



40

45

50

55




Preparation No.	R	MS	Analytical data
11		No ion	¹ H-NMR (300 MHz, CDCl ₃): δ 3.24 (t, 2H), 3.58 (t, 2H), 3.92 (s, 3H), 7.28 (d, 2H), 8.00 (d, 2H) ppm. IR λ 3354, 3267, 3047, 3009, 2956, 1718, 1611, 1554, 1428, 1310, 1282, 1160cm ⁻¹ m.p. 129 – 130.5°C
12 ^a		234 (M-H), 253 (MNH ₄ ⁺)	¹ H-NMR (300 MHz, DMSO-D ₆): δ 3.32 (m, 2H), 3.47 (m, 2H), 6.97 (broad s, 2H), 7.46 (m, 2H), 7.56 (m, 2H), 7.83 (m, 1H), 7.94 (d, 1H), 8.06 (d, 1H) ppm. IR λ 3335, 3261, 3051, 1598, 1549, 1317, 1167cm ⁻¹ m.p. 176 - 178°C

a. 2-(1-naphthyl)ethanesulfonylchloride was purchased from TCI Tokyo Kasei Kogyo Co., Ltd.

PREPARATION 13

2-(Cyclopentyl)ethanesulfonamide

[0102]



[0103] A solution of 2-(cyclopentyl)ethanesulfonyl chloride (14.1g, 71.4mmol) in dry tetrahydrofuran (40ml) was saturated with gaseous ammonia at 0°C. The resulting solution was stirred at room temperature under nitrogen for 2 hours and then concentrated under vacuum. The residue was dissolved in ethyl acetate (50ml) and water (50ml) and the aqueous phase was then acidified to pH 2 with 2.0M aqueous hydrochloric acid. The organic phase was separated and then washed with water (2 x 30ml), dried (sodium sulfate) and concentrated under vacuum. Purification of the


residue by chromatography on silica (500g) using 65/35 pentane/ethyl acetate as eluant gave the title compound as an off-white solid (6.48g), R_f 0.7 (pentane/ethyl acetate 1:1).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 1.12 (m, 2H), 1.48 - 1.68 (m, 4H), 1.73 - 1.94 (5H, m), 3.10 (m, 2H), 4.55 (broad s, 2H) ppm
LRMS (+ve ion) found: m/z 195 (MNH_4^+). $\text{C}_7\text{H}_{15}\text{NO}_2\text{S} + \text{NH}_4^+$ requires m/z 195

PREPARATION 14

N-[6-Chloro-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-(1-naphthyl)ethanesulfonamide

[0104]




[0105] To a solution of 3-[4,6-dichloro-5-(2-methoxyphenoxy)-2-pyrimidinyl]pyridazine, (0.06g, 0.17mmol) in dimethylsulfoxide (4ml) was added potassium carbonate (0.13g, 0.94mmol) immediately followed by 2-(1-naphthyl)ethanesulfonamide (0.044g, 0.18mmol). The mixture was stirred vigorously for 72 hours at 90°C and then quenched with hydrochloric acid solution (2M, 4ml). Ice-cold water (5ml) was added and a white precipitate was observed. The resultant mixture was partitioned between water (10ml) and dichloromethane (3x10ml). The combined organic extracts were washed with water (3x10ml), dried (magnesium sulfate) and concentrated under vacuum, yielding a yellow oil. Trituration with 1 ml of ice cold water, followed by filtration gave the title compound as a white solid (0.088g), m.p. 191.5 °C. $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ 3.6 (t, 2H), 3.98 (s, 3H), 4.12 (t, 2H), 6.91 (t, 1H), 7.02 (d, 1H), 7.1-7.3 (m, 7H), 7.7 (d, 1H), 7.8 (t, 1H), 8.3 (d, 1H), 9.3 (d, 1H) ppm.



IR (NaCl disk) λ 2996.5, 2913.0, 1436.9, 1406.2, 1057.2 cm^{-1} .



LRMS (+ve ion) found: m/z 549 (MH^+). $\text{C}_{27}\text{H}_{22}^{35}\text{ClN}_5\text{O}_4\text{S} + \text{H}$ requires m/z 549.

[0106] The compounds of the following tabulated preparations of the general formula:



were prepared by a similar method to that of Preparation 14 using the appropriate sulfonamide starting materials and the dichloropyrimidine of Preparation 3.


No.	R	Mpt °C	LRMS m/z =	Analytical data
15		142.8	516.4 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 3.18 (t, 2H), 3.95 (s, 3H), 4.10 (t, 2H), 4.91 (bs, 1H), 6.9-7.2 (m, 8H), 7.62 (m, 1H), 8.4 (d, 1H), 9.3 (d, 1H) ppm. IR λ 2996.9, 2913.3, 1437.0, 1406.5, 1057.1 and 935.7 (cm ⁻¹)
16		121.1	491.2 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 1.0 (bm, 2H), 1.5 (bm, 3H), 1.8 (bm, 4H), 2.3 (t, 2H), 3.7 (t, 2H), 3.95 (s, 3H), 6.8-7.2 (m, 4H), 7.7 (m, 1H), 8.5 (m, 1H), 9.3 (d, 1H) ppm IR λ 2996.2, 2913.3, 1562.3, 1540.1, 1437.1, 1406.1, 1057.3 (cm ⁻¹)

17		117.8	556.4 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 3.25 (t, 2H), 3.9 (s, 3H), 3.95 (s, 3H), 4.2 (t, 2H), 6.9-7.2 (m, 4H), 7.3 (d, 2H), 7.7 (bs, 1H), 7.9 (d, 2H), 8.4 (d, 1H), 8.7 (d, 1H), 9.3 (bs, 1H) ppm. IR λ 2996.1, 2913.0, 1435.2, 1406.5, 1057.0 cm ⁻¹ .
18		168.9	498.0 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 3.2 (t, 2H), 3.95 (s, 3H), 4.1 (t, 2H), 6.9 (t, 1H), 7.05 (d, 1H), 7.1-7.3 (m, 7H), 7.6 (dd, 1H), 8.4 (d, 2H), 8.7 (bs, 1H), 9.3 (d, 1H) ppm.

EXAMPLE 1

N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-(1-naphthyl)ethanesulfonamide

[0107]



[0108] To a solution of *N*-[6-chloro-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-(1-naphthyl)ethanesulfonamide (0.088g, 0.17mmol) (Preparation 14) in methanol (5ml) was added sodium methoxide (25%w/v in methanol, 1.0 ml). The mixture was stirred vigorously for 72 hours at 60°C. and then quenched with aqueous hydrochloric acid (2M, 1ml). Ice-cold water (2ml) was added and a white precipitate formed. The resultant mixture was partitioned between water (5 ml) and dichloromethane (3x10ml). The combined organic extracts were washed with water (3x10ml), dried (magnesium sulfate) and concentrated under vacuum to give the title compound as a yellow solid (95% pure by HPLC). (0.065g).


¹H-NMR (300 MHz, CDCl₃) δ 3.55 (t, 2H), 3.9 (s, 3H), 4.05 (t, 2H), 4.12 (s, 3H), 6.85 (t, 1H), 6.9 (d, 1H), 7.1 (m, 2H), 7.2 (m, 1H), 7.3 (m, 3H), 7.4 (m, 1H), 7.65 (m, 1H), 7.75 (d, 1H), 7.85 (d, 1H), 8.25 (d, 1H), 9.2 (d, 1H) ppm. LRMS (-ve ion) found: m/z 542 (M-H). C₂₈H₂₅N₅O₅S-H requires m/z 542

IR (NaCl disk) λ 2360.6, 2253.7, 1584.9, 1498.6, 1405.6, 1328.9, 1096.2, 907.1 cm⁻¹

[0109] The compounds of the following tabulated Examples of the general formula:

5

10



15

were prepared by a similar method to that of Example 1 using the appropriate 6-chloropyrimidines of Preparations 15-18.

20

25

30





35

40

45


50

55

No.	R	LRMS m/z =	Analytical data
2		512 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 3.1 (t, 2H), 3.9 (s, 3H), 4.05 (t, 2H), 4.15 (s, 3H), 6.85 (m, 3H), 6.95 (m, 1H), 7.1 (m, 4H), 7.6 (dd, 1H), 8.35 (d, 1H), 8.8 (bs, 1H), 9.2 (d, 1H) ppm.
			IR λ 3203.9, 2950.0, 1692.0, 1583.1, 1501.6, 1454.5, 1394.9, 1332.2, 1096.8, 733.1 cm ⁻¹
3		486 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 1.0 (m, 2H), 1.4-1.55 (m, 4H), 1.65 (m, 2H), 1.75 (m, 3H), 3.7 (t, 2H), 3.9 (s, 3H), 4.15 (s, 3H), 6.85 (t, 3H), 6.95 (d, 1H), 7.05 (m, 2H), 7.55 (m, 1H), 8.4 (d, 1H), 8.6 (s, 1H), 9.2 (d, 1H) ppm.
			IR λ 2951.9, 2253.8, 1584.7, 1497.8, 1455.2, 1333.2, 1253.8, 1096.0, 908.6, 732.3 cm ⁻¹
4		536 [M-H] ⁻	¹ H-NMR (300 MHz, CDCl ₃): δ 3.2 (t, 2H), 3.9 (s, 3H), 4.05 (s, 3H), 4.08 (t, 2H), 6.85 (t, 1H), 6.95 (d, 1H), 7.05 (m, 2H), 7.15 (d, 2H), 7.6 (m, 1H), 7.9 (d, 2H), 8.35 (d, 1H) ppm.
			IR λ 3194.9, 2952.0, 2253.9, 1694.0, 1499.0, 1396.0, 1097.0, 1022.2, 908.9, 732.1 cm ⁻¹
5		494.1496 [MH] ⁺	¹ H-NMR (300 MHz, CDCl ₃): δ 3.15 (t, 2H), 4.0 (s, 3H), 4.05 (t, 2H), 4.1 (s, 3H), 6.9 (t, 1H), 7.0 (d, 1H), 7.15 (m, 7H), 7.7 (dd, 1H), 8.5 (d, 1H), 8.65 (bs, 1H), 9.3 (d, 1H) ppm.

Claims

1. A compound of formula (I):



wherein:

R¹ is selected from
 (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl), (CR⁷R⁸)_n-het¹, (CR⁷R⁸)_n-aryl¹, NR⁹R¹⁰ and (CR⁷R⁸)_n-het², where R⁷ and R⁸ are
 independently selected from H and C₁₋₆ alkyl, and where
 R⁹ and R¹⁰ are independently selected from H or C₁₋₆ alkyl (optionally substituted by one of aryl¹, het¹, het²
 or (C₃₋₈ cycloalkyl));
 n is 2-6;
 R² is

- a) phenyl, optionally fused with het¹ or het²,
- b) naphthyl, optionally fused with het¹ or het², or
- c) het²,

said groups (a), (b) and (c) optionally substituted by C₁₋₆ alkyl, O(C₁₋₆ alkyl), halo, het³, het⁴, aryl², CO₂R¹¹,
 OC(O)R¹¹, CONR¹¹R¹², or S(O)_pR¹¹ ;
 R³ is

- e) C₁₋₆ alkyl,
- f) C₂₋₆ alkenyl,
- g) C₂₋₆ alkynyl,
- h) C₃₋₈ cycloalkyl

Where groups (e), (f), (g) and (h) may be optionally substituted by
 OR¹¹, halo, NHC(O)C₁₋₆ alkyl, Ohet¹, Ohet², OC(O)NHhet¹, OC(O)NHhet², NH₂, NHC(O)Ohet² or NHC(O)
 NHhet²;

X is O, S(O)_p, NH or a direct link;

Y is O, S(O)_p, or NH;

p is 0, 1 or 2;

R⁴, R⁵ and R⁶ are each independently selected from

H, halo, S(O)_pR⁹, het¹, het², aryl¹, O(C₁₋₆ alkyl) and C₁₋₆ alkyl (optionally substituted by halo, OR⁹ or NH₂);

R¹¹ and R¹² are independently selected from H and C₁₋₆ alkyl;

wherein "aryl¹" is a C₆₋₁₄ aromatic carbocycle, including mono-, bi- and tri-cyclic systems;

"aryl²" is a C₆₋₁₀ aromatic carbocycle, including mono- and bi-cyclic systems;

"het¹" is a 3-8 membered ring containing 1-3 heteroatoms, each independently selected from N, O and S, said
 ring being saturated or partially unsaturated and optionally benzofused;

"het²" is a 5 or 6 membered aromatic ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being optionally benzofused;

"het³" is a 3-6 membered ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being saturated or partially unsaturated and optionally benzofused;

"het⁴" is a 5 or 6 membered aromatic ring containing 1-3 heteroatoms, each independently selected from N, O and S, said ring being optionally benzofused;
and wherein

"het¹", "het²", and "aryl¹" may optionally be substituted by 1 to 3 substituents independently selected from halo, CO₂R⁹, OCOR⁹, OH, het⁴, S(O)_pR¹¹, O(C₁₋₆ alkyl) or C₁₋₆ alkyl (optionally substituted by OH, O(C₁₋₆ alkyl) or halo);

a 6-14 membered aromatic carbocycle includes phenyl, naphthyl, indenyl, anthryl and phenanthryl;

and the pharmaceutically acceptable salts, solvates, prodrugs and polymorphs thereof.

2. A compound, salt, solvate or prodrug according to claim 1 wherein the pyrimidine ring is attached at the 3 or 4 position of the pyridazine ring.
3. A compound, salt, solvate or prodrug according to any previous claim wherein R¹ is (CR⁷R⁸)_n-aryl¹, (CR⁷R⁸)_n-het², or (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl) and where n is 2, 3, 4, 5 or 6.
4. A compound, salt, solvate or prodrug according to any previous claim wherein R¹ is (CR⁷R⁸)_n-aryl¹ or (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl) and where n is 2 or 3.
5. A compound, salt, solvate or prodrug according to any previous claim wherein R¹ is (CR⁷R⁸)_n-aryl¹ or (CR⁷R⁸)_n-(C₃₋₈ cycloalkyl) and where n is 2.
6. A compound, salt, solvate or prodrug according to any previous claim wherein R² is phenyl or het², both optionally substituted by C₁₋₆ alkyl, O(C₁₋₆ alkyl), halo, het³, het⁴, aryl², CO₂R¹¹, OC(O)R¹¹ or CONR¹¹R¹².
7. A compound, salt, solvate or prodrug according to any previous claim wherein R² is phenyl optionally substituted by C₁₋₆ alkyl, O(C₁₋₆ alkyl), halo, het³, het⁴, aryl², CO₂R¹¹, OC(O)R¹¹ or CONR¹¹R¹².
8. A compound, salt, solvate or prodrug according to any previous claim wherein R² is phenyl optionally substituted by C₁₋₃ alkyl, O(C₁₋₃ alkyl), F or Cl.
9. A compound, salt, solvate or prodrug according to any previous claim wherein R³ is C₁₋₆ alkyl, C₂₋₆ alkynyl or C₃₋₈ cycloalkyl, said alkyl, alkynyl and cycloalkyl groups optionally substituted by OR¹¹, halo, NHC(O)C₁₋₆ alkyl, Ohet¹, Ohet², OC(O)NHhet¹ or OC(O)NHhet².
10. A compound, salt, solvate or prodrug according to any previous claim wherein R³ is C₂₋₃ alkynyl, or C₁₋₃ alkyl (optionally substituted by OR¹¹, halo, NHC(O)C₁₋₆ alkyl, Ohet¹, Ohet², OC(O)NHhet¹ or OC(O)NHhet²).
11. A compound, salt, solvate or prodrug according to any previous claim wherein R³ is C₁₋₃ alkyl, CH₂CH₂OH, CH₂C≡CH, CH₂CH₂F or CH₂CH₂OCH₃.
12. A compound, salt, solvate or prodrug according to any previous claim wherein R⁴, R⁵ and R⁶ are selected from H, O(C₁₋₆ alkyl), S(C₁₋₆ alkyl), phenyl, halo, het¹, het² and C₁₋₆ alkyl (optionally substituted by halo or NH₂).
13. A compound, salt, solvate or prodrug according to any previous claim wherein R⁴ and R⁵ are hydrogen and R⁶ is selected from H, O(C₁₋₆ alkyl) and C₁₋₆ alkyl (optionally substituted by halo).
14. A compound, salt, solvate or prodrug according to any previous claim wherein R⁴ and R⁵ are hydrogen and R⁶ is selected from H or C₁₋₆ alkyl.

15. A compound, salt, solvate or prodrug according to any previous claim wherein R⁷ and R⁸ are independently selected from H and C₁₋₃ alkyl.
- 5 16. A compound, salt, solvate or prodrug according to any previous claim wherein R⁷ and R⁸ are independently selected from H and CH₃.
17. A compound, salt, solvate or prodrug according to any previous claim wherein R⁷ and R⁸ are H.
- 10 18. A compound, salt, solvate or prodrug according to any previous claim wherein R⁹ and R¹⁰ are selected from H and C₁₋₃ alkyl (optionally substituted by aryl¹, het¹, het² and C₃₋₈ cycloalkyl).
19. A compound, salt, solvate or prodrug according to any previous claim wherein R⁹ and R¹⁰ are selected from H and C₁₋₃ alkyl (optionally substituted by aryl¹ or het¹).
- 15 20. A compound, salt, solvate or prodrug according to any previous claim wherein R⁹ and R¹⁰ are H.
21. A compound, salt, solvate or prodrug according to any previous claim wherein R¹¹ and R¹² are selected from H and C₁₋₃ alkyl.
- 20 22. A compound, salt, solvate or prodrug according to any previous claim wherein R¹¹ and R¹² are selected from H and CH₃.
23. A compound, salt, solvate or prodrug according to any previous claim wherein X is O, NH or a direct link.
- 25 24. A compound, salt, solvate or prodrug according to any previous claim wherein X is O.
25. A compound, salt, solvate or prodrug according to any previous claim wherein Y is O or NH.
- 30 26. A compound, salt, solvate or prodrug according to any previous claim wherein Y is O.
27. A compound, salt, solvate or prodrug according to any previous claim wherein n is 2, 3 or 4.
28. A compound, salt, solvate or prodrug according to any previous claim wherein n is 2.
- 35 29. A compound, salt, solvate or prodrug of formula (I) according to claim 1 wherein the substituents are as specified in the compounds of the Examples described herein.
30. A compound according to claim 1 which is selected from:


40 N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-(1-naphthyl)ethanesulfonamide,
 N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-(4-fluorophenyl)ethanesulfonamide,
 N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-cyclopentylethanesulphonamide,
 N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-(4-carboxyphenyl)ethanesulfonamide,
 45 N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(3-pyridazinyl)-4-pyrimidinyl]-2-phenylethanesulphonamide

and the salts and solvates thereof.
- 50 31. A pharmaceutical composition comprising a substance according to any one of claims 1 to 30, and a pharmaceutically acceptable diluent, carrier or adjuvant.
32. A substance according to any one of claims 1 to 30 for use in medicine.
- 55 33. The use of a substance according to any one of claims 1 to 30 in the manufacture of a medicament for the treatment of an endothelin mediated condition.
34. A method of treatment of a condition mediated by endothelin comprising administration of a therapeutically-effective amount of a substance according to any one of claims 1 to 30.


35. A substance according to any one of claims 1 to 30 for use in the treatment of an endothelin mediated condition.

36. A process for making a compound of formula (I) as defined in claim 1 which comprises:




- 5 a. condensation of compounds of formula (V) and (VI), where R^{10a} is a C_{1-6} alkyl or phenyl group, to make a compound of formula (IV):



- 35 b. chlorination of a compound of formula (IV), in the presence of a base, and where required with an inert solvent, to make a compound of formula (III):






- c. reaction of a compound of formula (III) with a compound of formula $R^1SO_2NH_2$, in the presence of a base, heated, to make a compound of formula (II)



25

d. reaction of a compound of formula (II) with a compound of formula R^3YH , in the presence of a base, to make a compound of formula (I).



55

37. A compound of formula (IV) as defined in claim 36.

38. A compound of formula (III) as defined in claim 36.

39. A compound of formula (II) as defined in claim 36.

40. A compound of formula (V) as defined in claim 36.

5

10

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 30 7528

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	EP 0 882 719 A (YAMANOUCHI PHARMA CO LTD) 9 December 1998 (1998-12-09) * page 6, line 28 - line 33 * * page 11, line 18 - line 19 * * tables 1,3-9 * * claim 1 *	1-40	C07D403/04 C07D237/08 A61K31/505 A61P9/08
A	US 4 698 091 A (BRUNNER HANS-GEORG ET AL) 6 October 1987 (1987-10-06) compounds 103, 107, 109 and 110 * column 1, line 12 - line 16; table 1 *	1-40	
A	US 5 883 090 A (CHRISTADLER MARIA ET AL) 16 March 1999 (1999-03-16) * abstract; claim 1; example 8 *	1-40	
A	US 5 707 966 A (SCHACHT AARON L ET AL) 13 January 1998 (1998-01-13) * example 69 *	40	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07D
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 20 December 2001	Examiner Guspanova, J
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.02 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 7528

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-12-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0882719	A	09-12-1998	AT 201202 T	15-06-2001
			AU 703386 B2	25-03-1999
			AU 1171097 A	14-07-1997
			BR 9612061 A	23-02-1999
			DE 69612874 D1	21-06-2001
			DE 69612874 T2	04-10-2001
			EP 0882719 A1	09-12-1998
			JP 3087968 B2	18-09-2000
			US 6083955 A	04-07-2000
			CA 2238723 A1	26-06-1997
			ES 2156305 T3	16-06-2001
			HU 0000474 A2	28-12-2000
			WO 9722595 A1	26-06-1997
			TW 414792 B	11-12-2000
US 4698091	A	06-10-1987	BR 8303011 A	31-01-1984
			CA 1237133 A1	24-05-1988
			DE 3379544 D1	11-05-1989
			EP 0096657 A2	21-12-1983
			ES 523054 D0	01-03-1985
			ES 8503340 A1	01-06-1985
			IL 68911 A	31-07-1986
			JP 59005169 A	12-01-1984
			PH 21023 A	30-06-1987
			ZA 8304117 A	28-03-1984
US 5883090	A	16-03-1999	DE 19537548 A1	10-04-1997
			AU 7211996 A	30-04-1997
			BR 9606668 A	30-09-1997
			CA 2207243 A1	17-04-1997
			CN 1168137 A	17-12-1997
			CZ 9701768 A3	15-10-1997
			WO 9713758 A1	17-04-1997
			EP 0796250 A1	24-09-1997
			HU 9801879 A2	28-06-1999
			JP 10511118 T	27-10-1998
			NO 972612 A	08-08-1997
			PL 320638 A1	13-10-1997
			SK 73597 A3	06-05-1998
			ZA 9608483 A	20-05-1997
US 5707966	A	13-01-1998	AU 684918 B2	08-01-1998
			AU 1975295 A	18-09-1995
			BR 9506979 A	18-11-1997
			CA 2183464 A1	09-08-1995
			CN 1147205 A	09-04-1997

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 7528

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-12-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5707966 A		CZ 9602584 A3	11-06-1997
		EP 0672658 A1	20-09-1995
		FI 963451 A	03-09-1996
		HU 76330 A2	28-08-1997
		IL 112795 A	28-01-2001
		JP 9509937 T	07-10-1997
		NO 963684 A	28-10-1996
		NZ 282588 A	19-12-1997
		PL 320637 A1	13-10-1997
		RU 2148585 C1	10-05-2000
		TW 401403 B	11-08-2000
		WO 9523609 A1	08-09-1995
		US 5705487 A	06-01-1998
		US 5726159 A	10-03-1998
		US 5914319 A	22-06-1999
		US 5710130 A	20-01-1998
<hr/>			